HCV core antigen and HCV-RNA in HIV/HCV co-infected patients with different HCV genotypes

BMC Infectious Diseases

Volumn 14, Issue 1, 2014, Pages

  Garbuglia, Anna R ^a   Monachetti, Alessia ^b   Galli, Claudio ^c   Sabatini, Rosella ^a   Ferreri, Monica L ^b   Capobianchi, Maria R ^a   Bagnarelli, Patrizia ^b  

^a NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^b UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^c ABBOTT DIAGNOSTICS   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS C ANTIGEN; PEGINTERFERON; RIBAVIRIN; VIRUS RNA;

ADULT; AGED; ANTIGEN DETECTION; ARTICLE; CLINICAL EVALUATION; CORRELATION ANALYSIS; DISEASE ASSOCIATION; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; MICROBIAL KINETICS; MIXED INFECTION; RELAPSE; RNA ANALYSIS; SENSITIVITY ANALYSIS; SEROLOGY; BLOOD; CHRONIC HEPATITIS C; COMPLICATION; EVALUATION STUDY; GENETICS; HEPACIVIRUS; IMMUNOLOGY; MIDDLE AGED; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; COINFECTION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C ANTIGENS; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; RIBAVIRIN; RNA, VIRAL;

EID: 84901405699     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-14-222     Document Type: Article

References (44)

1. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989, 244:359-362. 10.1126/science.2523562, 2523562.
2. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005, 5:558-567. 10.1016/S1473-3099(05)70216-4, 16122679.
3. Hatzakis A, Wait S, Bruix J, Buti M, Carballo M, Cavaleri M, Colombo M, Delarocque-Astagneau E, Dusheiko G, Esmat G, Esteban R, Goldberg D, Gore C, Lok ASF, Manns M, Marcellin P, Papatheodoridis G, Peterle A, Prati D, Piorkowsky N, Rizzetto M, Roudot-Thoraval F, Soriano V, Thomas HC, Thursz M, Valla D, van Damme P, Veldhuijzen IK, Wedemeyer H, Wiessing L, Zanetti AR, Janssen HLA, et al. The state of hepatitis B and C in Europe: report from the hepatitis B and C summit conference. J Viral Hepat 2011, 18(suppl. 1):1-16.
4. European Association for the Study of the Liver EASL clinical practice guidelines: management of hepatitis C virus infection. J Hepatol 2011, 55:245-264. European Association for the Study of the Liver.
5. Hofmann WP, Sarrazin C, Zeuzem S. Current standards in the treatment of chronic hepatitis C. Dtsch Arztebl Int 2012, 109:352-358. 3364529, 22675406.
6. Halfon P, Bourlière M, Pénaranda G, Khiri H, Ouzan D. Real-time PCR assays for hepatitis C virus (HCV) RNA quantitation are adequate for clinical management of patients with chronic HCV infection. J Clin Microbiol 2006, 44:2507-2511. 10.1128/JCM.00163-06, 1489518, 16825372.
7. Pyne MT, Konnick EQ, Phansalkar A, Hillyard DR. Evaluation of the Abbott investigational use only RealTime hepatitis C virus (HCV) assay and comparison to the Roche TaqMan HCV analyte-specific reagent assay. J Clin Microbiol 2009, 47:2872-2878. 10.1128/JCM.02329-08, 2738061, 19625475.
8. Bortoletto G, Campagnolo D, Mirandola S, Comastri G, Severini L, Pulvirenti FR, Alberti A. Comparable performance of TMA and Real-Time PCR in detecting minimal residual hepatitis C viraemia at the end of antiviral therapy. J Clin Virol 2011, 50:217-220. 10.1016/j.jcv.2010.11.010, 21195023.
9. Bossler A, Gunsolly C, Pyne MT, Rendo A, Rachel J, Mills R, Miller M, Sipley J, Hillyard D, Jenkins S, Essmyer C, Young S, Lewinski M, Rennert H. AmpliPrep/COBAS TaqMan® automated system for hepatitis C virus (HCV) quantification in a multi-center comparison. J Clin Virol 2011, 50:100-103. 10.1016/j.jcv.2010.10.020, 21145783.
10. Chevaliez S. Virological tools to diagnose and monitor hepatitis C virus infection. Clin Microbiol Infect 2011, 17:116-121. 10.1111/j.1469-0691.2010.03418.x, 21054664.
11. Morota K, Fujinami R, Kinukawa H, Machida T, Ohno K, Saegusa H, Takeda K. A new sensitive and automated chemiluminescent microparticle immunoassay for quantitative determination of hepatitis C virus core antigen. J Virol Methods 2009, 157:8-14. 10.1016/j.jviromet.2008.12.009, 19135481.
12. Ross RS, Viazov S, Salloum S, Hilgard P, Gerken G, Roggendorf M. Analytical performance characteristics and clinical utility of a novel assay for total hepatitis C virus core antigen quantification. J Clin Microbiol 2010, 48:1161-1168. 10.1128/JCM.01640-09, 2849592, 20107102.
13. Medici MC, Furlini G, Rodella A, Fuertes A, Monachetti A, Calderaro A, Galli S, Terlenghi L, Olivares M, Bagnarelli P, Costantini A, De Conto F, Sainz M, Galli C, Manca N, Landini MP, Dettori G, Chezzi C. Hepatitis C virus core antigen: analytical performances, correlation with viremia and potential applications of a quantitative, automated immunoassay. J Clin Virol 2011, 51:260-265.
14. Descamps V, Op de Beck A, Plassart C, Brochot E, Francois C, Helle F, Adler M, Bourgeois N, Degré D, Duverlie G, Castelain S. Strong correlation between liver and serum levels of hepatitis C virus core antigen and RNA in chronically infected patients. J Clin Microbiol 2012, 50:465-468. 10.1128/JCM.06503-11, 3264181, 22162563.
15. Mederacke I, Wedemeyer H, Ciesek S, Steinmann E, Raupach R, Wursthorn K, Manns MP, Tillmann HL. Performance and clinical utility of a novel fully automated quantitative HCV-core antigen assay. J Clin Virol 2009, 46:210-215. 10.1016/j.jcv.2009.08.014, 19766055.
16. Kesly R, Polat H, Terzi Y, Kurtoglu MG, Uyar Y. Comparison of a newly developed automated and quantitative hepatitis C virus (HCV) core antigen test with the HCV RNA assay for clinical usefulness in confirming anti-HCV results. J Clin Microbiol 2011, 49:4089-4093. 10.1128/JCM.05292-11, 3233016, 21940466.
17. Kamili S, Drobeniuk J, Araujo AC, Hayden TM. Laboratory diagnostics for hepatitis C virus infection. Clin Infect Dis 2012, 55(S1):S43-S48.
18. Miedouge M, Saune K, Kamar N, Rieu M, Rostaing L, Izopet J. Analytical evaluation of HCV core antigen and interest for HCV screening in haemodialysis patients. J Clin Virol 2010, 48:18-21. 10.1016/j.jcv.2010.02.012, 20233674.
19. Icardi G, Ansaldi F, Bruzzone BM, Durando P, Lee S, de Luigi C, Crovari P. Novel approach to reduce the hepatitis C virus (HCV) window period: clinical evaluation of a new enzyme-linked immunosorbent assay for HCV Core antigen. J Clin Microbiol 2001, 39:3110-3114. 10.1128/JCM.39.9.3110-3114.2001, 88305, 11526137.
20. Leary TP, Gutierrez RA, Muerhoff AS, Birkenmeyer LG, Desai SM, Dawson GJ. A chemiluminescent, magnetic particle-based immunoassay for the detection of hepatitis C virus core antigen in human serum or plasma. J Med Virol 2006, 78:1436-1440. 10.1002/jmv.20716, 16998880.
21. Mederacke I, Potthoff A, Meyer-Olson D, Meier M, Raupach R, Manns MP, Wedemeyer H, Tillmann HL. HCV core antigen testing in HIV- and HBV-coinfected patients, and in HCV-infected patients on hemodialysis. J Clin Virol 2012, 53:110-115. 10.1016/j.jcv.2011.11.009, 22177274.
22. Verbeeck J, Stanley MJ, Shieh J, Celis L, Huyck E, Wollants E, Morimoto J, Farrior A, Sablon E, Jankowski-Hennig M, Schaper C, Johnson P, Van Ranst M, Van Brussel M. Evaluation of Versant hepatitis C virus genotype assay (LiPA) 2.0. J Clin Microbiol 2008, 46:1901-1906. 10.1128/JCM.02390-07, 2446848, 18400913.
23. Martró E, González V, Buckton AJ, Saludes V, Fernández G, Matas L, Planas R, Ausina V. Evaluation of a new assay in comparison with reverse hybridization and sequencing methods for hepatitis C virus genotyping targeting both 5' noncoding and nonstructural 5b genomic regions. J Clin Microbiol 2008, 46:192-197. 10.1128/JCM.01623-07, 2224264, 17989191.
24. Zanetti AR, Romanò L, Brunetto M, Colombo M, Bellati G, Tackney C. Total HCV core antigen assay: a new marker of hepatitis C viremia for monitoring the progress of therapy. J Med Virol 2003, 70:27-30. 10.1002/jmv.10355, 12629640.
25. Takahashi M, Saito H, Higashimoto M, Atsukawa K, Ishii H. Benefit of hepatitis C virus core antigen assay in prediction of therapeutic response to interferon and ribavirin combination therapy. J Clin Microbiol 2005, 43:186-191. 10.1128/JCM.43.1.186-191.2005, 540104, 15634970.
26. Vermehren J, Susser S, Berger A, Perner D, Peiffer KH, Allwinn R, Zeuzem S, Sarrazin C. Clinical utility of the ARCHITECT HCV Ag assay for early treatment monitoring in patients with chronic hepatitis C genotype 1 infection. J Clin Virol 2012, 55:17-22. 10.1016/j.jcv.2012.05.008, 22698697.
27. Loggi E, Cursaro C, Scuteri A, Grandini E, Martello Panno A, Galli S, Furlini G, Bernardi M, Galli C, Andreone P. Patterns of HCV-RNA and HCV Core antigen in the early monitoring of standard treatment for chronic hepatitis C. J Clin Virol 2013, 56:291-295.
28. Schuettler CG, Thomas C, Discher T, Friese G, Lohmeyer J, Schuster R, Schaefer S, Gerlich WH. Variable ratio of hepatitis C virus RNA to viral Core antigen in patient sera. J Clin Microbiol 2005, 42:1977-1981.
29. Gastaminza P, Dryden KA, Boyd B, Wood MR, Law M, Yeager M, Chisari FV. Ultrastructural and biophysical characterization of hepatitis C virus particles produced in cell culture. J Virol 2010, 84:10999-11009. 10.1128/JVI.00526-10, 2953183, 20686033.
30. Murayama A, Sugiyama N, Watashi K, Masaki T, Suzuki R, Aizaki H, Mizuochi T, Wakita T, Kato T. Japanesereferencepanel of bloodspecimens for evaluation of hepatitis C virus RNA and core antigen quantitative assays. J Clin Microbiol 2012, 50:1943-1949. 10.1128/JCM.00487-12, 3372108, 22495557.
31. Durante-Mangoni E, Vallefuoco L, Sorrentino R, Lossa D, Perna E, Molaro R, Braschi U, Zampino R, Sodano G, Adinolfi LE, Utili R, Portella G. Clinico-pathological significance of hepatitis C virus core antigen levels in chronic infection. J Med Virol 2013, 85:1913-1918. 10.1002/jmv.23672, 23897630.
32. Kuo YH, Chang KC, Wang JH, Tsai PS, Hung SF, Hung CH, Chen CH, Lu SN. Is hepatitis C virus core antigen an adequate marker for community screening?. J Clin Microbiol 2012, 50:1989-1993. 10.1128/JCM.05175-11, 3372126, 22461676.
33. Ergunay K, Sener B, Alp A, Karakaya J, Hascelick G. Utility of a commercial quantitative hepatitis C virus core antigen assay in a diagnostic laboratory setting. Diagn Microbiol Infect Dis 2011, 70:486-491. 10.1016/j.diagmicrobio.2011.04.011, 21767705.
34. Ohshawa M, Kato K, Tanno K, Ikai K, Fujishima Y, Okayama A, Turin TC, Onoda T, Suzuki. Seropositivity for anti-HCV core antigen is independently associated with increased all-cause, cardiovascular, and liver disease-related mortality in hemodialysis patients. J Epidemiol 2011, 21:491-499. 10.2188/jea.JE20100187, 3899466, 22001541.
35. Turner J, Bansi L, Gilson R, Gazzard B, Walsh J, Pillay D, Orkin C, Phillips A, Easterbrook P, Johnson M, Porter K, Schwenk A, Hill T, Leen C, Anderson J, Fisher M, Sabin C, . UK Collaborative HIV Cohort (UK CHIC) Study The prevalence of hepatitis C virus (HCV) infection in HIV-positive individuals in the UK - trends in HCV testing and the impact of HCV on HIV treatment outcomes. J Viral Hepat 2010, 17:569-577. UK Collaborative HIV Cohort (UK CHIC) Study.
36. Taylor LE, Swan T, Mayer KH. HIV coinfection with hepatitis C virus: evolving epidemiology and treatment paradigms. Clin Infect Dis 2012, 55(S1):s33-s42. 3491862, 22715212.
37. Anggorowati N, Yano Y, Heriyanto DS, Hinonce HT, Utsumi T, Mulya DP, Subronto YW, Hayashi Y. Clinical and virological characteristics of hepatitis B or C virus co-infection with HIV in Indonesian patients. J Med Virol 2012, 84:857-865. 10.1002/jmv.23293, 22499006.
38. Righi E, Beltrame A, Bassetti M, Lindstrom V, Mazzarello G, Dentone C, Di Biagio A, Ratto S, Viscoli C. Therapeutical aspects and outcome of HIV/HCV coinfectedpatients treated with pegylated interferon plus ribavirin in an Italian cohort. Infection 2008, 36:358-361. 10.1007/s15010-008-7319-5, 18642111.
39. Cornberg M, Razavi HA, Alberti A, Bernasconi E, Buti M, Cooper C, Dalgard O, Dillion JF, Flisiak R, Forns X, Frankova S, Goldis A, Goulis I, Halota W, Hunyady B, Lagging M, Largen A, Makara M, Manolakopoulos S, Marcellin P, Marinho RT, Pol S, Poynard T, Puoti M, Sagalova O, Sibbel S, Simon K, Wallace C, Young K, Yurdaydin C, et al. A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. Liver Internat 2011, 31(suppl. 2):30-60.
40. Stroffolini T, D'Egidio PF, Aceti A, Filippini P, Puoti M, Leonardi C, Almasio PL, . and the DAVIS (Drug Addicted, HCV Prevalence in Italy) participating Centers An epidemiological, observational, cross-sectional, multicenter study: Hepatitis C virus infection among drug addicts in Italy. J Med Virol 2012, 84:1608-1612. 10.1002/jmv.23370, 22930509, and the DAVIS (Drug Addicted, HCV Prevalence in Italy) participating Centers.
41. Danta M, Semmo N, Fabris P, Brown D, Pybus OG, Sabin CA, Bhagani S, Emery VC, Dusheiko GM, Klenerman P. Impact of HIV on host-virus interactions during early hepatitis C virus infection. J Infect Dis 2008, 197:1558-1566. 10.1086/587843, 18419344.
42. Shen T, Chen X, Zhang W, Xi Y, Cao G, Zhi Y, Wang S, Xu C, Wei L, Lu F, Zhuang H. A higher correlation of HCV core antigen with CD4+ T cell counts compared with HCV RNA in HCV/HIV-1 coinfected patients. PLoS ONE 2011, 6:e23550. 10.1371/journal.pone.0023550, 3155566, 21858166.
43. Xu C-H, Shen T, Zheng J-J, Tu J, Zhang W-D, Lu F-M. Higher dN/dS ratios in the HCV core gene, but not in the E1/HVR1 gene, are associated with human immunodeficiency virus-associated immunosuppression. Arch Virol 2012, 157:2153-2162. 10.1007/s00705-012-1390-z, 22825695.
44. Millum J, Menikoff J. Streamlining ethical review. Ann Intern Med 2010, 2010(153):655-657.